The FDA approves an HIV med, expanding the non-nuke class.
In mid January, the FDA approved Intelence (etravirine, TMC-125) for treatment of HIV. The new non-nuke aims to help those positive people whose virus is resistant to the other three meds in that class—Sustiva, Viramune and Rescriptor; it has not been approved for people just starting meds. The dose is two 100 mg tablets twice a day in a combo with drugs from other classes. Intelence, whose most common side effects in trials were rash and nausea, can’t be teamed with the other non-nukes, nor with some protease inhibitors. Details at AIDSmeds.com (search for “Intelence”) or your doctor’s office.
NEW! Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
